Juvenile Arthritis Data For Novartis' Ilaris Also Supports Role In Gouty Arthritis
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis' canakinumab shows promise in the first of two Phase III studies in systemic juvenile idiopathic arthritis, a severe and apparently distinct form of juvenile arthritis.